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Abstract: Bioactive peptides have been identified in a range of foods, including plant, 
milk and muscle, e.g., beef, chicken, pork and fish muscle proteins. Bioactive peptides 
from food proteins offer major potential for incorporation into functional foods and 
nutraceuticals. The aim of this paper is to present an outline of the bioactive peptides 
identified in the muscle protein of meat to date, with a focus on muscle protein from 
domestic animals and fish. The majority of research on bioactives from meat sources has 
focused on angiotensin-1-converting enzyme (ACE) inhibitory and antioxidant peptides.  
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1. Introduction 
Food proteins have long been recognized for their nutritional and functional properties. The 
nutritional properties of proteins are associated with their amino acid content in conjunction with the 
physiological utilization of specific amino acids upon digestion and absorption [1,2]. On the other 
hand, the functional properties of proteins relate to their contribution to the physiochemical and 
sensory properties of foods [2,3]. In recent years, a considerable amount of research has also focused 
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on the liberation of bioactive peptides which are encrypted within food proteins, with a view to 
utilizing such peptides as functional food ingredients aimed at health maintenance.  
Bioactive peptides have been defined as “food derived components (genuine or generated) that, in 
addition to their nutritional value exert a physiological effect in the body” [4]. Interestingly, within the 
parent protein sequence, the peptides are inactive and thus must be released to exert an effect. These 
bioactive peptides are usually 2–20 amino acid residues in length, although, some have been reported 
to be >20 amino acid residues. Bioactive peptides may be absorbed through the intestine where they 
subsequently enter the circulatory system intact to exert various physiological effects, or they may 
produce local effects in the digestive tract [5]. Food derived bioactive peptides have been shown  
to display a wide range of physiological functions including antihypertensive, antioxidative,   
opioid agonistic, immunomodulatory, antimicrobial, prebiotic, mineral binding, antithrombotic and 
hypocholesterolemic effects [6].  
Meat and fish provide valuable sources of protein for many populations around the world; 
furthermore, meat and fish proteins offer huge potential as novel sources of bioactive peptides.   
To date, bioactive peptides displaying antihypertensive, antioxidant, antimicrobial and antiproliferative 
effects have been found in the hydrolysates of meat and fish proteins [7–10]. 
History of Bioactive Peptide Discovery  
The first food-derived bioactive peptide was identified in 1950 when Mellander reported that casein 
phosphorylated peptides enhanced vitamin D-independent bone calcification in rachitic infants [11]. 
However, interest in this field has increased considerably in the last two decades, with the majority  
of research focusing on the identification of bioactive peptides from milk proteins [12,13].   
Bioactive peptides are inactive or latent in the parent protein but are released in an active form after 
proteolytic digestion [14]. Methods employed in the proteolytic digestion of parent proteins include 
hydrolysis by digestive enzymes [15], plant and bacterial proteases [16,17], and following microbial 
fermentation [18–20]. 
The most widely reported bioactive peptides from milk and other food sources display 
antihypertensive activity, particularly those peptides which inhibit the action of angiotensin-1-converting 
enzyme (ACE) [21,22]. Indeed, currently a number of commercial products which contain such 
peptides have been released onto the market. Perhaps the two most widely known products available 
are both fermented milk-based products, i.e., Calpis
® and Evolus
®. Calpis
® is a sour milk product from 
Japan which contains the antihypertensive peptides VPP and IPP both derived from milk caseins. 
Evolus
® is a Finnish product that claims to reduce blood pressure. Evolus
® also contains the peptides 
VPP and IPP which correspond to the fragments of β-casein f (84–86) and κ-casein f (74–76) [14]. 
Various milk protein hydrolysates which claim to contain bioactive peptides are also available as food 
ingredients. For example C12
®, a casein derived peptide supplied by DMV International, claims to 
reduce blood pressure.  
2. Production of Bioactive Peptides 
While numerous methods have been utilized to release bioactive peptides from food proteins, 
enzymatic hydrolysis of whole protein is the most widely used technique. For example, a number of Nutrients 2011, 3  
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bioactive peptides have been isolated from meat using digestive enzymes such as pepsin, trypsin and 
chymotrypsin. Indeed, peptic digestion of porcine skeletal muscles has resulted in the generation of 
numerous ACE inhibitory peptides [23,24]. Various proteases from bacterial, animal and plant origin 
have also been used to generate bioactive peptides from meat sources [10,25,26]. 
Several researchers have described the isolation of bioactive peptides following bacterial fermentation 
of milk proteins where lactobacilli have been commonly used [27–29]. However, microbial fermentation 
of meat proteins has been less successful, presumably due to the poor proteolytic activity of the 
lactobacilli used in meat fermentations [30,31]. Indeed, to the best of our knowledge, no bioactive 
peptides have been produced from the microbial fermentation of muscle proteins. 
Identification of Bioactive Peptides 
Following the hydrolysis of the protein substrate (Figure 1), the hydrolysates are assayed for 
various bioactivities. After the detection of bioactivity within the crude protein hydrolysates, the 
hydrolysates are then fractionated based on peptide size, which is typically performed using 
ultrafiltration [32–34]. The hydrolysate fraction displaying the highest bioactivity is then further 
purified to separate individual peptides using different techniques, most notably reverse phase high 
performance liquid chromatography (RP-HPLC) or gel permeation chromatography [15,22,35]. 
Individual peptide fractions are identified using the combined techniques of mass spectrometry and 
protein sequencing. Lastly, a synthetic version of the peptide is synthesized and the assay is repeated to 
verify bioactivity [21,36,37]. 
Figure 1. Procedure for the isolation and identification of bioactive peptides from food 
proteins, adapted from Arihara & Ohata [30]. 
 Nutrients 2011, 3  
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3. Antihypertensive Peptides 
Bioactive peptides have been found in a wide range of foods, and as already mentioned, the most 
extensively researched of these are the antihypertensive peptides, particularly those which inhibit   
ACE [3,22]. ACE inhibitory peptides were first discovered in snake venom [38] and since then 
numerous synthetic ACE inhibitors have been produced, with Captopril being the most common. 
Additionally, Captopril and other synthetic ACE inhibitors are known to exert various side-effects 
such as coughing, taste disturbances and skin rashes [35,39]. These side effects, coupled with   
the fact that hypertension affects one third of the Western worlds’ population and is a known   
risk factor for stroke and cardiovascular disease, has contributed to the ongoing search for food   
derived antihypertensive peptides for exploitation as antihypertensive agents in functional foods and 
nutraceuticals [40,41]. 
3.1. Mechanism of ACE Inhibition 
ACE, or kininase ІІ, is a dipeptidyl carboxy peptidase (EC 3.4.15.1) found in various tissues in the 
body and is integral to the moderation of blood pressure and normal heart function [40].   
In the rennin-angiotensin system, ACE catalyses the conversion of the inactive form of angiotensin I 
(Ang І) to the potent vasoconstrictor angiotensin II (Ang ІІ). Additionally, ACE is involved in the 
deactivation of the hypotensive peptide, bradykinin [32]. This is as a result of ACE cleaving the   
C-terminal dipeptide from Ang І (His-Leu) and bradykinin. Ang ІІ is a documented potent 
vasoconstrictor which acts directly on vascular smooth muscle cells. Ang ІІ is also responsible for the 
expansion of vascular volume via sodium retention and fluid retention [42–45]. Bradykinin is 
responsible for uterine and ileal smooth muscle contraction, enhanced vascular permeability, activation 
of peripheral and C fibers and increases in mucous secretion [42,46]. Furthermore, and more notably 
bradykinin contributes to vasodilation by advancing the assembly of arachidonic acid metabolites, 
nitric oxide, and endothelium-derived hyperpolarizing factor in the vascular endothelium [42,47]. 
Therefore, ACE inhibitors function by maintaining the balance between the associated vasoconstrictive 
and salt-retentive attributes of Ang ІІ with the vasodilatory effect of bradykinin. The balance is 
maintained by decreasing the production of Ang ІІ and reducing the degradation of bradykinin [42]. 
While synthetic ACE inhibitors, such as Captopril function by directly blocking the action of ACE, 
ACE inhibitory peptides function by reacting with ACE, thus ACE is unavailable to cleave Ang І and 
prevent the production of the vasoconstrictor Ang ІІ [48]. In the past decade, it has been reported that 
muscle proteins from animals are a viable source of ACE inhibitory peptides in vitro and may potentially 
be incorporated into nutraceutical products to exert antihypertensive effects in vivo [10,25,49]. 
3.1.1. ACE Inhibitor Type Peptides 
An important factor when discussing ACE inhibitory peptides isolated from food proteins is the 
discrepancy between ACE inhibitory activity of peptides in vitro and their antihypertensive effect 
in vivo [3,30]. ACE inhibitory food peptides can be divided into three categories, depending on their 
inhibitory activity following preincubation with ACE [33]. The first group of ACE inhibitory peptides 
is known as “true inhibitor type” peptides. The IC50 value of these peptides is not affected by Nutrients 2011, 3  
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preincubation with ACE. The second category of peptides, known as “substrate type” peptides are 
hydrolyzed by ACE resulting in weak inhibitory activity. Finally, the third category is “pro-drug type” 
inhibitors. The peptides in this category are converted to “true inhibitor type” peptides by ACE or 
proteases of the digestive tract. In vivo studies have demonstrated that only peptides belonging to the 
groups of true inhibitor type or pro-drug type reduce the systolic blood pressure of spontaneously 
hypertensive rats (SHR) [30].  
To date, the majority of ACE inhibitory peptides found in meat can be classified as true inhibitor 
type peptides [10,50,51]. These peptides may act in one of two ways, first the peptide may bind to the 
active site of the ACE enzyme or second it may bind to an inhibitor site located on the ACE enzyme 
thereby modifying the protein confirmation and preventing the substrate (Ang І) from binding to the 
enzyme active site [52]. 
3.1.2. Absorption of ACE Inhibitory Peptides 
When determining or extrapolating the in vivo efficacy of potential ACE inhibitory peptides in 
humans using the SHR model, differences in bioavailability of nutrients between both species is an 
important consideration. Bioavailability is the term used to “express the proportion of the total amount 
of a nutrient that can be absorbed and utilized” [53]. The bioavailability of a nutrient is in part 
controlled by the physicochemical properties of the nutrient; these include molecular weight and size, 
lipophilicity, pKa, charge and solubility. Factors which affect the variability of nutrient absorption and 
which are species-dependent include the physiological factors of pH, gastrointestinal (GI) motility, 
transit time, intestinal permeability as well as the diverse groups of enzymes and transporters [54–56]. 
It has been proposed that the larger relative absorptive surface area of the human GI tract results in 
faster absorption of nutrients and a larger uptake than that of the rat [57]. Finally, when extrapolating 
the results from in vivo studies of SHR to human subjects, it is important to incorporate dosage of 
nutrient, form of nutrient, period of administration, metabolic state of subjects and control diets 
used [58]. 
For an ACE inhibitory peptide to function in vivo, it must first enter the circulatory system intact. 
Peptides may be hydrolyzed by enzymes of the digestive tract as well as peptidases associated with the 
brush border membrane, cytoplasm or serum [59,60]. To date, studies documenting the intestinal 
absorption of ACE inhibitory peptides in vitro have employed the Caco-2 cell monolayer [61], as  
it is generally acknowledged that this cell line is a suitable model to predict the permeability of 
intestinal epithelial cells to pharmaceuticals [62–64]. Interestingly, the occurrence of peptides which 
demonstrate ACE inhibitory activity in vitro but poor antihypertensive activity in vivo may be 
explained by the possible alteration of peptides prior to reaching the target ACE enzyme in the 
circulatory system [62,65]. The opposite has also proven true, in that peptides determined to have poor 
ACE inhibitory activity in vitro have demonstrated a significant systolic blood pressure (SBP) 
lowering effect in vivo, possibly due to intestinal modification [23,66]. 
The bioavailability of the β-casein ACE inhibitory peptide LHLPLP was determined by evaluating 
it’s resistance to brush border peptidases, serum peptidases as well as identifying the mechanism of 
transepithelial transport [67]. It was concluded that LHLPLP was partly hydrolyzed to HLPLP by 
brush border peptidases and HLPLP was rapidly absorbed by the Caco-2 cell monolayer in a Nutrients 2011, 3  
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concentration-dependent manner. Furthermore, the peptide remained “practically intact” after one hour 
incubation with human plasma and remained unbound to plasma proteins. This suggests that the 
peptide LHLPLP is hydrolyzed to HLPLP, the minimum active form, which is then readily absorbed 
across the intestinal epithelium by paracellular diffusion and is stable to serum proteases. This offers 
the possibility that HLPLP may be a viable alternative in the treatment or prevention of hypertension 
in humans. 
The well documented ACE inhibitory milk peptides IPP and VPP have also been subject to in vitro 
permeability studies [59]. Both peptides were found to be readily transported across the intestinal 
epithelium of the various models used. It has been reported that IPP avoids gastrointestinal digestion 
and can enter the circulatory system of humans intact [68]. Studies involving the oral administration of 
foods rich in both IPP and VPP have demonstrated that such foods exhibit blood pressure lowering 
effects on hypertensive patients [69–71]. This clearly demonstrates that certain ACE inhibitory 
peptides are sufficiently well absorbed by the body to be effective at reducing blood pressure of 
hypertensive subjects. The challenge for researchers now is to identify bioactive peptides in vitro 
which can enter the circulatory system intact and remain active at their target site. 
3.1.3. Structure Correlation of ACE Inhibitory Peptides 
As stated previously, the mode of action of the majority of ACE inhibitory peptides is thought to be 
as competitive substrates for ACE. The structure activity relationships of ACE inhibitory peptides has 
not yet been confirmed due to the assorted amino acid sequence properties of ACE inhibitory peptides 
identified to date [21,30]. The tripeptide sequence at the C-terminal end of ACE inhibitory peptides 
has been suggested as the controlling factor of ACE inhibitory peptides, which regularly contains 
hydrophobic amino acid residues. It has been reported that at the penultimate positions, aliphatic (V, I, 
and A), basic (R) and aromatic (Y and F) residues are preferred, while aromatic (W, Y, and F), proline 
(P) and aliphatic (I, A, L and M) residues are favored at the ultimate position of the C-terminal end of 
the peptide [33,72–76]. This is because of the interaction of these residues with the three hydrophobic 
sub-sites located on the active site of ACE [49,77]. The positive charge associated with arginine at the 
C-terminus has also been associated with the ACE inhibitory activity of some peptides, as has the 
presence of lysine (K) which possesses a positive charge on the є-amino group at the C-terminus [27]. 
Another common feature of ACE inhibitory peptides is the hydrophobic nature of the N-terminal end 
of the peptide [52,78]. In the case of peptides greater than three amino acids in length, it has been 
suggested that the presence of hydroxyproline (Hyp) is critical for the binding of peptides to the active 
sites of ACE [79]. Furthermore, the overall hydrophobicity of the peptide is important. Hydrophilic 
peptides possess weak or no ACE inhibitory activity, since hydrophilic peptides are incompatible with 
the active sites of ACE. Indeed, inhibition of ACE is achieved by hydrophobic peptides which display 
high affinity to the active sub-sites of ACE [8,21,80]. 
3.2. Antihypertensive Peptides from Animal Sources 
The generation of force (i.e., contraction) by skeletal muscle is the responsibility of the muscle 
proteins, actin and myosin. Both of these proteins are associated with two distinct types of muscle 
filaments. Myosin proteins are associated with the thick filaments of skeletal muscle while actin is Nutrients 2011, 3  
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associated with the thin filaments of skeletal muscle. Also present in the thin filaments are the proteins 
troponin and tropomyosin [3,81]. In striated muscle, the myosin thick filaments extend along the thin 
filaments of actin and are known as sacromeres. Sacromeres are further longitudinally repeated to form 
myofibrils. Myofibrils are then arranged in parallel to form myofibers, these myofibers then form 
muscle fibers. The muscle proteins arranged in parallel bands result in skeletal and cardiac muscle 
being striped or striated in appearance [3,81]. Contraction of striated muscle is due to the interaction of 
the thick and thin filaments. Nerve impulses release Ca
2+ from the sacroplasmic reticulum, which pass 
through the myofibrils resulting in the sliding of myosin and actin filaments over one another, causing 
the sacromeres to shorten resulting in muscle contraction [82]. Interestingly, ACE inhibitory peptides 
have been identified in the hydrolysates of actin, myosin and troponin [50,83,84]. 
3.2.1. Antihypertensive Peptides from Myosin Sources 
Arihara and colleagues [23] identified two ACE inhibitory pentapeptides from the thermolysin 
digestion of porcine myosin. These were named myopentapeptides A and B and their sequences 
determined. The amino acid sequence of myopentapeptide A was found to be MNPPK, which 
corresponded to positions 79–83 on the myosin heavy chain, while myopentapeptide B, with the   
amino acid sequence ITTNP, corresponded to positions 306–310 on the myosin heavy chain. The 
antihypertensive activities of myopentapeptide A and myopentapeptide B were investigated in SHR, in 
addition to other thermolysin hydrolysates of porcine skeletal muscle proteins. Administration of 
myopentapeptide A and myopentapeptide B at a concentration of 1 mg per kilogram of animal weight 
resulted in a maximum decrease in SBP of 23.4 ± 3.0 mmHg and 21.0 ± 3.1 mmHg after 6 h, 
respectively. At 24 h, the SBP of both test groups was still significantly lower than that of the control 
group, indicating that both myopentapeptide A and myopentapeptide B are potent antihypertensive 
peptides in vivo [66].  
Another ACE inhibitory octapeptide VKKVLGNP was discovered corresponding to positions   
47–54 on the myosin light chain [84]. This peptide was generated following the digestion of crude 
myosin light chain with pepsin. The IC50 value of this peptide was calculated to be 28.5 µM. 
Following the administration of this purified peptide to SHR at a concentration of 10 mg per kilogram 
of animal weight, the SBP decreased up to 3 h post-administration with SBP returning to the pre 
administration value after 9 h. It was therefore postulated that the peptide VKKVLGNP was an 
effective hypotensor in vivo. 
Porcine skeletal muscle also was found to be a source of antihypertensive peptides when crude 
myosin B was hydrolyzed with pepsin. [83]. Indeed, within this hydrolysate a novel peptide M6 was 
identified with the amino acid sequence KRVITY. This peptide corresponded to positions 191–196 on 
the myosin heavy chain. The SBP of SHR was immediately reduced following oral administration of 
M6 peptide with a maximum decrease of 23 mmHg after 6 h, with the SBP of test animals returning to 
the control after 9 h. This reduction in SBP of SHR would indicate that the M6 peptide is a potent 
hypotensor in vivo. Furthermore, the M6 peptide retained its ACE inhibitory activity after heating the 
myosin B to 98 °C for 10 min prior to hydrolysis by pepsin. Retention of ACE inhibitory activity after 
such thermal treatment clearly indicates that bioactivity is retained even after the cooking process. Nutrients 2011, 3  
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3.2.2. Antihypertensive Peptides from Troponin Sources 
In a study to identify the most active ACE inhibitory peptides from porcine skeletal muscle, a 
bioactive peptide of 9 amino acids was released from the regulatory protein troponin C [85]. This 
peptide with the amino acid sequence RMLGQTPTK had an IC50 value of 34 µM and was categorized 
as being a non-competitive inhibitor [50]. Subsequently, the same researchers described a novel ACE 
inhibitory peptide from the pepsin hydrolysate of crude porcine troponin [24]. This peptide with the 
amino acid sequence KRQKYDI (corresponding to amino acid positions 198–204 of troponin T) had 
an IC50 value of 26.2 µM. Incubation of the peptide with ACE resulted in a decrease in the observed 
IC50 value suggesting that the peptide KRQHYDI is a substrate type inhibitor. Administration of the 
peptide to SHR resulted in temporary reduction of SBP. It has therefore been suggested that the 
peptide KRQHYDI may inhibit ACE activity in vivo in the short term. 
As demonstrated in the above studies, bioactive peptides can be released from the digestion of meat 
proteins by various digestive enzymes. ACE inhibitory peptides were released following in vitro 
gastric simulated digestion of pork meat using a combination of the digestive enzymes pepsin and 
pancreatin [86]. The active ACE inhibitory peptides generated in this study were found to be 
homologous to the amino acid sequence of the muscle protein titin, representing the first documented 
ACE inhibitory peptides released from the myofibrillar protein titin. The amino acid sequence of the 
most active peptide present in this hydrolysate was identified as KAPVA, the IC50 value of this peptide 
was determined to be 46.56 µM. 
3.2.3. Antihypertensive Peptides from Collagen 
Connective tissue, which functions to convert force (i.e., contraction) into movement by attaching 
muscle to bone via robust strips of connective tissue called tendons, is mainly composed of fibrillar 
collagen. There are numerous collagens present in the extracellular matrix and they are the major 
structural constituent of connective tissue. All collagens contain repetition of the proline rich tripeptide 
Gly-X-Y; that forms the trimeric collagen triple helices [87]. 
Recently, it was reported that ACE inhibitory peptides were purified from the hydrolysate of bovine 
skin gelatine [34]. Five proteases were employed, Alcalase, α chymotrypsin, Neutrase, Pronase E, and 
trypsin. Hydrolysis was performed using sequential protease treatments and a three-step ultrafiltration 
membrane reactor. This involved collagen first being hydrolyzed by Alcalase, fractioned with a   
10 kDa membrane, followed by hydrolysis with Pronase E, fractionated with a 5 kDa membrane and 
finally hydrolyzed with collagenase and separated using a 1 kDa molecular weight cut-off (MWCO) 
membrane. Two peptides responsible for ACE inhibitory activity were subsequently isolated from this 
low molecular weight fraction. The first peptide referred to as EIIICIII, with the amino acid sequence 
GPV had an IC50 value of 4.7 µM, while the second peptide known as EIIICIV, with amino acid 
sequence GPL had an IC50 value of 2.55 µM.  
Chicken breast muscle was identified as a potential source of ACE inhibitory peptides by   
Saiga et al. 2003 [79]. The researchers fed two chicken breast muscle extracts to SHR, the first an 
untreated chicken muscle extract, the second a chicken muscle extract hydrolyzed with an Aspergillus 
protease. The blood pressure of SHR was significantly lowered after ingestion of both extracts.   Nutrients 2011, 3  
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A reduction in blood pressure occurred after 1 h and lasted until 4 h post-ingestion. The purification of 
ACE inhibitory peptides from Aspergillus protease- and gastric protease-hydrolyzed chicken breast 
muscle resulted in the identification of four peptides displaying strong ACE inhibitory effects. The 
peptide expressing the strongest ACE inhibitory activity referred to as P4 had amino acid sequence 
GFHypGTHypGLHypGF. The IC50 value of this peptide was determined as 42.4 µM, whose sequence 
along with the others identified was homologous to that of collagen [79]. Interestingly, an immediate 
decrease in the blood pressure of SHR was observed after intravenous administration of the P4 peptide 
(30 mg per kilogram of body weight). However, blood pressure returned to base pressure 60 min post 
administration, suggesting that the P4 peptide may not act as a long-term vasodepressor in vivo [36].  
It was also demonstrated that the P4 peptide is a non-competitive inhibitor of ACE. The presence of an 
aromatic amino acid at the antepenultimate position and phenylalanine at the C-terminal end of the 
peptide are responsible for the ACE inhibitory effect of the peptide. This supports the theory that the 
ACE inhibitory activity of peptides is based on the presence of hydrophobic amino acids located at the 
C-terminal end of the peptide.  
ACE inhibitory peptides were also detected following the hydrolysis of chicken collagen by an 
Aspergillus oryzae protease. The resulting hydrolysate was further hydrolyzed with four proteases, 
namely protease FP, protease A, amino G and protease N. Four peptides displaying ACE inhibitory 
activity were identified along with their individual IC50 values, GAHypGLHypGP (IC50 29.4 µM), 
GAHypGPAGPGGIHypGERG (IC50 45.6 µM), GLHypGSRGERGERGLHypG (IC50 60.8 µM) and 
finally GIHypGERGPVGPSG (IC50 43.4 µM). The chicken collagen hydrolysates were fed to SHR 
and a reduction in blood pressure was detected 2 h after administration of the hydrolysates with the 
greatest reduction occurring after 6 h. Following continuous long-term administration of chicken 
collagen hydrolysates to SHR a significant reduction in blood pressure was observed. It is therefore 
proposed that low molecular weight chicken collagen hydrolysates show long-term hypotensive effects 
in vivo and have potential as antihypertensive therapeutic agents. 
3.2.4. Antihypertensive Peptides from Miscellaneous Sources 
The first identified ACE inhibitory peptide from beef hydrolysate was reported to be a hexapeptide 
with the amino acid sequence VLAQYK; this peptide had an IC50 value of 32.06 µM and was isolated 
from the sacroplasmic proteins of beef rump [25]. Feeding this hexapeptide to SHR resulted in a 
significant reduction in SBP in addition to lower total and LDL cholesterol blood concentrations [88]. 
It was proposed that the hexapeptide VLAQYK is a potent ACE inhibitor with potential use in clinical 
applications and functional food products. Subsequently, the same research group explored the 
possibility that beef sacroplasmic protein hydrolysates may contain other peptides capable of ACE 
inhibitory activity. This was part of a larger investigation to determine if antihypertensive peptides were 
capable of exhibiting other bioactivities, namely antimicrobial and antiproliferative [10]. Four peptides 
were found to exhibit strong ACE inhibitory activity, the strongest of which was from the Alcalase 
hydrolyzed hydrolysate. Other bioactivities associated with these peptides will be discussed later.   
A summary of ACE inhibitory meat derived peptides is given in Table 1. Nutrients 2011, 3  
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Table 1. ACE inhibitory peptides from meat of domestic animals. Adapted with 
permission from American Chemical Society [3], Copyright 2005. 
Source  Amino Acid Sequence  Parent Protein Enzyme  IC50 (µM)  SHR 
a  Ref. 
pig ITTNP  myosin  thermolysin  549  ∆ 21.0 mmHg  [23,66]
 MNPPK  myosin  synthesized  945.5 ∆ 23.4 mmHg  [23,66]
 MNP  myosin  synthesized  66.6 ∆ 19.6 mmHg  [23,66]
 PPL  myosin  synthesized  >1000  ∆ 24.7 mmHg  [23,66]
 NPP  myosin  synthesized  290.5 ∆ 17.6 mmHg  [23,66]
 TNP  myosin  synthesized  207.4 ∆ 11.1 mmHg  [23,66]
 RMLGQTPTK  troponin pepsin  34  nt  [50,85]
 RMLGQTP  troponin pepsin  503  nt  [50] 
 VKKVLGNP  myosin  pepsin  28.5  ∆ 24.0 mmHg 
b [84] 
 KRVITY  myosin  pepsin  6.1 ∆ 23.0 mmHg 
b [83] 
 VKAGF  actin  pepsin  20.3  ∆ 17.0 mmHg 
b [83] 
 KRQKYDI  troponin  T  pepsin  26.2 ∆ 9.9 mmHg 
b [24] 
  KAPVA  titin  pepsin + pancreatin  46.56  nt  [86] 
  PTPVP  titin  pepsin + pancreatin  256.41  nt  [86] 
  ER  muscle  pepsin + pancreatin  667  nt  [86] 
  KLP  muscle  pepsin + pancreatin  500  nt  [86] 
  RPR  muscle  pepsin + pancreatin  382  nt  [86] 
chicken LKA  creatine kinase  thermolysin  8.5  nt  [89] 
 LKP  aldolase thermolysin  0.32 ∆ 75 mmHg 
c  [89] 
 LAP  muscle  thermolysin  3.2 ∆ 40.0 mmHg 
c [89] 
 FQKPKR  myosin  thermolysin  14  nt  [89] 
 FKGRYYP  creatine  kinase  thermolysin  0.55  ∆ 0 mmHg 
c [89] 
 IKW  muscle  thermolysin  0.21 ∆ 50.0 mmHg 
c [89] 
 GFXGTXGLXGF  muscle  Aspergillus protease +
gastric proteases 
42.4  ∆ 20 mmHg 
d [36,79]
 GAXGLXGP  collagen Aspergillus protease +
protease FP, A, G, N 
29.4 nt  [37] 
 GAXGPAGPGGIXGERG
LXG 
collagen  Aspergillus protease +
protease FP, A, G, N 
45.6 nt  [37] 
 GLXGSRGERGERGLXG collagen Aspergillus protease + 
protease FP, A, G, N 
60.8 nt  [37] 
 GIXGSRGERGPVGPSG  collagen Aspergillus protease + 
protease FP, A, G, N 
43.4 nt  [37] 
cow VLAQYK  muscle  thermolysin  + 
proteinase A 
32.06 +  [25,88]
 GFHI  muscle  proteinase  K  64.3  nt  [10] 
 DFHING  muscle  alcalase  50.5  nt  [10] 
 FHG  muscle  thermolysin  + 
proteinase A 
52.9 nt  [10] 
 GLSDGEWQ  muscle  thermolysin  + 
proteinase A 
117 nt  [10] Nutrients 2011, 3  
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Table 1. Cont. 
  GPV  skin gelatin  alcalase + pronase E 
+ collagenase 
4.67 nt  [34] 
  GPL  skin gelatin  alcalase + pronase E 
+ collagenase 
2.55 nt  [34] 
a The maximum decrease in systolic blood pressure in SHR upon oral administration of peptide at 1 mg/kg;  
b The maximum decrease in systolic blood pressure in SHR upon oral administration of peptide at 10 mg/kg; 
c The maximum decrease in systolic blood pressure in SHR upon intravenous administration of peptide at 
10 mg/kg; 
d The maximum decrease in systolic blood pressure in SHR upon intravenous administration of 
peptide at 30 mg/kg; nt: Not tested in spontaneously hypertensive rats.  
4. Antihypertensive Peptides from Fish Sources 
ACE inhibitory peptides from fish sources were first identified in sardine meat over twenty years 
ago [90]. Since then ACE inhibitory peptides have been found in various fish species, including 
shellfish, tuna, bonito, salmon and sardine [49,72–75,91]. 
There have been several reports of crude fish protein hydrolysates containing ACE inhibitory 
peptides. Following the hydrolysis of purified catfish protein with the commercial enzyme Protamex
® 
ACE inhibitory peptides were released, with the majority being found in the soluble protein fraction [92]. 
A crude enzyme extract from the viscera of sardine was used to hydrolyze the protein contained within 
the head and viscera of the fish species know as sardinelle. The resulting hydrolysate contained a high 
concentration of peptides displaying low hydrophobicity with molecular masses between 200 and 
600 Da [93]. Pacific Hake fish protein subjected to simulated gastrointestinal digestion was reported to 
contain ACE inhibitory activity. Most inhibitory peptides were reported to be short chained, polar and 
containing few hydrophobic amino acids in their sequence [94]. 
Antihypertensive Peptides from Fish By-Products 
A major issue for food producers is discarded by-products of food processing. Adding value to 
waste streams is very appealing to food producers, as the by-products are usually incorporated into low 
economic value products such as animal feed. The frame protein of Alaskan Pollock which is normally 
discarded as an industrial by-product was mined for ACE inhibitory peptides [95]. Frame protein was 
first hydrolyzed with pepsin and then separated into five fractions depending on molecular weight, the 
most active ACE inhibitory peptides were found in the fraction <1 kDa. From this fraction, a novel 
peptide was isolated with an amino acid sequence FGASTRGA and an IC50 value of 14.7 µM. 
The normally discarded yellowfin sole frame protein was identified as another source of ACE 
inhibitory peptides [96]. Using α-chymotrypsin, a peptide with a molecular mass of 1.3 kDa was 
isolated with the corresponding amino acid sequence MIFPGAGGPEL. It was demonstrated that this 
peptide reduced the SBP of SHR over 9 h when administrated at 10 mg per kilogram of animal body 
weight. The SBP of SHR was reduced by 22 mmHg at 3 h, a reduction which was comparable to the 
group treated with Captopril. Reduction in SBP remained after 9 h, suggesting that MIFPGAGGPEL is 
an effective antihypertensive agent in vivo. Frame protein hydrolysate derived from tuna frame protein 
was investigated for novel ACE inhibitory peptides [51]. Six proteases were used, with pepsin Nutrients 2011, 3  
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hydrolysates displaying the highest ACE inhibitory activity. Consecutive purification steps resulted in 
the isolation of an ACE inhibitory peptide of 21 amino acids in length. The peptide with the amino 
acid sequence GDLGKTTTVSNWSPPKYKDTP had an IC50 value of 11.28 µM and actively 
decreased the SBP of SHR for up to 9 h after oral administration, with a maximum decrease of 
21 mmHg after 6 h. 
Following oral administration of a thermolysin hydrolysate from chum salmon muscle, the SBP of 
SHR was significantly reduced when compared to that of the controls. The greatest reduction in SBP 
occurred after 4 h suggesting that short chain peptides were responsible for the blood pressure 
lowering effect, since reduction in blood pressure occurred soon after administration. Indeed,   
a reduction in SBP 6 to 8 h after administration is associated with peptides of greater chain length, 
because larger peptides are converted from substrate to true ACE inhibitors in vivo [74]. The SBP of 
all test groups returned to initial levels after 24 h, demonstrating that hydrolysates of chum salmon are 
temporary hypotensors. The amino acid sequences of the six di-peptides identified from the 
thermolysin digest of chum salmon were WA, VW, WM, MW, IW, and LW. The IC50 values of these 
six peptides were determined as 277.3, 2.5, 98.6, 9.8, 4.7 and 17.4 µM, respectively. Interestingly, it 
was found that a change in the amino acid sequence of some dipeptides resulted in a change in the 
inhibitory mechanism as well as a change in the reported IC50 value [97]. For example, the peptide 
MW has an IC50 value of 9.8 µM and is a non-competitive inhibitor of ACE. When the amino acid 
sequence was changed to WM, the IC50 value increased to 98.6 µM and mode of inhibition changed to 
competitive, indicating that the amino acid composition of peptides as well as position of amino acids 
in the peptide sequence contributes to the ACE inhibitory activity of peptides.  
The pepsin hydrolysate of Bigeye tuna dark muscle was reported to contain the ACE   
inhibitory peptide WPEAAELMMEVDP, with a molecular mass of 1581 Da and an IC50 value of 
21.6  µM [49]. Employing Lineweaver-Burk plots, the authors determined that the peptide forms 
enzyme-substrate-inhibitor and enzyme-inhibitor complexes to lower the efficiency of ACE in vitro. 
Administration of this peptide to SHR resulted in a maximum decrease in SBP between 3 and 6 h. The 
SBP of test animals remained lower than control animals (~15 mmHg) after 10 h proving that 
WPEAAELMMEVDP is an effective hypotensor in vivo. 
Following the hydrolysis of shark meat with the protease SM98011 from Bacillus sp. SM98011, 
four ACE inhibitory peptides were identified [98]. Three of the peptides were reported as being novel 
ACE inhibitory peptides, the amino acid sequences of these peptides were EY, FE and CF, with   
IC50 values of 1.98, 2.68 and 1.45 µM, respectively. 
Fujita et al. [72] developed a thermolysin hydrolysate from “Katsuo-bushi”, a traditional Japanese 
food processed from dried bonito. This hydrolysate was administered to thirty hypertensive and 
borderline hypertensive human subjects in a small scale clinical trial. The hydrolysate contained the 
previously reported ACE inhibitory peptide LKPNM [75]. Following eight weeks of administration of 
the dried bonito hydrolysate, the SBP of subjects was reduced by 12.55 ± 1.5 mmHg. This clearly 
demonstrates that the thermolysin hydrolsate of dried bonito is sufficiently well absorbed in humans  
to effectively reduce the SBP of hypertensive and borderline hypertensive subjects in vivo. The 
hydrolysate has been approved as Foods for Specified Health Use (FOSHU) by the Ministry of Health 
and Welfare in Japan [72]. A summary of ACE inhibitory fish derived peptides is given in Table 2. Nutrients 2011, 3  
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Table 2. ACE inhibitory peptides derived from meat of fish. Adapted with permission 
from American Chemical Society [3], Copyright 2005. 
Source  Amino acid sequence  Parent protein Enzyme  IC50 (µM) SHR 
a  Ref. 
bonito IKPLNY  muscle  thermolysin  43  nt  [75] 
 IVGRPRHQG  actin  thermolysin  2.4  nt  [75] 
 IWHHT  actin  thermolysin  5.8  nt  [75] 
 ALPHA  actin  thermolysin  10  nt  [75] 
 FQP  actin  thermolysin  12  nt  [75] 
 LKPNM  muscle thermolysin  2.4 ∆ 23.0 mmHg 
b [72,75] 
 IY  actin  thermolysin  2.31  ∆ 19.0 mmHg 
b [72,75] 
 DYGLYP  muscle thermolysin  62  nt  [75] 
 LKP  muscle thermolysin  0.32  ∆ 18.0 mmHg 
b [72] 
 IWHHT  actin  thermolysin  3.5 ∆ 26.0 mmHg 
b [72] 
 IKP  muscle thermolysin  6.9 ∆ 20.0 mmHg 
b [72] 
 IVGRPR  actin  thermolysin  300  ∆ 25.0 mmHg 
b [89] 
salmon WA  muscle  thermolysin  277.3  nt  [74] 
 VW  muscle thermolysin  2.5  nt  [74] 
 WM  muscle thermolysin  96.6  nt  [74] 
 MW  muscle thermolysin  9.9  nt  [74] 
 IW  muscle thermolysin  4.7  nt  [74] 
 LW  muscle thermolysin  17.4  nt  [74] 
sardine MF  muscle  alcalase  44.7  nt  [73] 
 RY  muscle alcalase  51  nt  [73] 
 MY  muscle alcalase  193  nt  [73] 
 LY  muscle alcalase  38.5  nt  [73] 
 YL  muscle alcalase  82  nt  [73] 
 IY  muscle alcalase  10.5  nt  [73] 
 VF  muscle alcalase  43.7  nt  [73] 
 GRP  muscle alcalase  20  nt  [73] 
 RFP  muscle alcalase  330  nt  [73] 
 AKK  muscle alcalase  3.13  nt  [73] 
 RVY  muscle alcalase  205.6  nt  [73] 
 GWAP  muscle alcalase  3.86  nt  [73] 
 KY  muscle alcalase  1.63  nt  [73] 
 VY  muscle alcalase  10  ∆ 7.0 mmHg  [99,100]
tuna PTHIKWGD  muscle  acid  nd  nt  [101] 
 
GDLGKTTTVSNWSP
PKYKDTP 
frame protein  pepsin  11.28  ∆ 21.0 mmHg  [51] 
 WPEAAELMMEVDP  dark  muscle  pepsin  21.6 ∆ 18.0 mmHg  [49] 
alaska 
pollack 
GPL  skin  alcalase + pronase 
+ collagenase 
2.65 nt  [102] 
 
GPM  skin  alcalase + pronase 
+ collagenase 
17.13 nt  [102] 
 FGASTRGA  frame  protein  pepsin  14.7  nt  [95] Nutrients 2011, 3  
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Table 2. Cont. 
yellowfin 
sole 
MIFPGAGGPEL frame  protein  α chymotrypsin  28.7  ∆ 22.0 mmHg  [96] 
shark EY  muscle  protease  SM98011 1.98  nt  [98] 
 FE  muscle  protease  SM98012 2.68  nt  [98] 
 CF  muscle  protease  SM98013 1.45  nt  [98] 
a The maximum decrease in systolic blood pressure in SHR upon oral administration of peptide at 10 mg/kg;  
b The maximum decrease in systolic blood pressure in SHR upon oral administration of peptide at 60 mg/kg; 
nt: Not tested in SHR; nd: IC50 of peptide was not determined. 
5. Antioxidant Peptides 
Antioxidants are known to be beneficial to human health as they may protect the body against 
molecules known as reactive oxygen species (ROS), which can attack membrane lipids, protein and 
DNA. This in turn can be a causative factor in many diseases such as cardiovascular disease, diabetes, 
cancer and Alzheimer’s disease. Lipid oxidation can cause deterioration of food quality and a 
reduction in the shelf-life of a food product, while the consumption of foods containing lipid   
oxidation products has been linked to various diseases, including cancers, diabetes and cardiovascular 
disease [103–106]. 
The use of natural antioxidants in foodstuffs is appealing because of the potential health risk 
associated with synthetic antioxidants in vivo [107–110]. Antioxidant peptides have been found in 
numerous foodstuffs including milk [111], wheat [16], potato [22] and fungi [112]. In the past number 
of years, a great deal of research has focused on antioxidant peptides sourced from fish, while the 
research on antioxidant peptides from the hydrolysates of domesticated animal muscle is limited. 
There are a number of methods available to measure antioxidant potential of various food components 
based on the ability of potential antioxidants to scavenge ROS, free radicals or prevent oxidation in 
model systems, some of which are discussed below. 
5.1. Antioxidant Peptides from Fish Sources 
The hydrolysates of mackerel were found to contain peptides exhibiting antioxidant activity  
in vitro [113]. Peptides released by the hydrolysis of mackerel with Protease N inhibited the 
autoxidation of linoleic acid, quenched the free radical α,α-diphenyl-β-picrylhydrazyl (DPPH) and 
reduced Fe
3+ to Fe
2+. The strongest antioxidant fraction of mackerel protein hydrolysate contained 
small peptides and free amino acids and had a molecular weight of 1400 Da. 
Alaska Pollack frame protein (APF) was found to contain the peptide LPHSGY, released after 
hydrolysis of APF by a crude enzyme extract contained within mackerel intestine. This peptide was 
responsible for the quenching of 35% of available hydroxyl radicals at a peptide concentration of  
53.6 µM. The authors proposed that a correlation existed between the observed antioxidant activity 
and the molecular weight of the peptides, with greater antioxidant activity associated with peptides of 
low molecular weight (<1 kDa) [114]. 
The antioxidant potential of Tilapia (common name for cichlid fish) protein hydrolysates was also 
demonstrated [115]. Hydrolysates generated with the enzymes Cyrotin-F, Protease A, Protease N, Nutrients 2011, 3  
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Flavourzyme and Neutrase showed significant ability to scavenge ROS and reduce ferric ions. The 
ability to effectively scavenge ROS was associated with the low molecular weight peptides present in 
the hydrolysates. Low molecular weight peptides were also responsible for the observed antioxidant 
activity in the hydrolysates of Silver carp following hydrolysis by Alcalase and Flavourzyme [116].  
In previous studies, it was noted that increasing the degree of hydrolysis produced greater numbers of 
low molecular weight peptides, which was associated with an increase in the radical scavenging ability 
of salmon muscle hydrolysate [97]. This phenomenon, however, was not observed in the hydrolysates 
of catfish protein isolate hydrolyzed with Protamex [92], where the ability of the hydrolysates to 
scavenge DPPH radicals or reduce Fe
3+ decreased with increasing degree of hydrolysis. An increase in 
the number of low molecular weight peptides did; however, result in an increase in the time required 
for lipid peroxidation products to accumulate in a model muscle washed system. This suggests that 
antioxidant ability of peptides in vitro depends on peptide size, amino acid composition of the peptide 
and presence of free amino acids within the hydrolysate. 
The peptides from Alcalase- and Flavourzyme-digested Yellow Stripe Trevally were shown to 
prevent oxidative damage to DNA using the Fenton reaction. The possible reason for this was   
that hydrolysates chelated Fe
2+ thus preventing it from reacting with H2O2 and forming hydroxyl 
radicals [117]. 
Seven antioxidant peptides were identified in the hydrolysates of proteins recovered from the waste 
stream of sardinelle processing [118]. The amino acid sequences of the seven peptides were LARL, 
GGE, LHY, GAH, GAWA, PHYL and GALAAH. All peptides were <600 Da and were deemed to be 
novel antioxidant peptides. It was reported that the peptide LHY displayed the highest DPPH radical 
scavenging activity, with an ability to scavenge 63% of available DPPH radical present at a peptide 
concentration of 150 µg/mL. 
Antioxidant peptides were generated from the hydrolysis of tuna dark muscle by-product by the 
commercial enzymes orientase (OR) and protease XXІІІ (PR) [119]. Antioxidant activity was 
determined by measuring the DPPH radical scavenging capacity and the ability of hydrolysates to 
inhibit or delay lipid peroxidation of linoleic acid. From the OR enzyme digest, a purified antioxidant 
peptide with the amino acid sequence LPTSEAAKY was identified as having the capacity to scavenge 
79.6% of available DPPH radicals, while also inhibiting lipid peroxidation of linoleic acid for   
7.13 days at a peptide concentration of 100 µg/mL. Following the hydrolysis of tuna dark muscle  
by-product with the enzyme PR, the peptide with amino acid sequence PMNYMVT was demonstrated 
to scavenge 85.2% of available DPPH radicals, while also inhibiting oxidation of linoleic acid for  
7.89 days at a peptide concentration of 100 µg/mL. Furthermore, when compared to the controls (butyl 
hydroxyanisol (BHA) and α-tocopherol employed in determination of lipid peroxidation inhibition, 
and  L-ascorbic acid in determination of DPPH radical scavenging ability), both peptides displayed 
similar if not higher activity. Therefore, it is clear that the peptides generated during the hydrolysis of 
tuna dark muscle by-product are effective in vitro antioxidants with potential for incorporation into 
foodstuffs as natural antioxidants.  
Hoki skin gelatin was hydrolyzed by the digestive enzymes pepsin, trypsin and α-chymotrypsin 
with the tryptic hydrolysates displaying the highest levels of antioxidant activity [120]. A single 
purified peptide, with the amino acid sequence HGPLGPL was identified as being responsible for the 
observed antioxidant activity of the tryptic hydrolysate. When the peptide HGPLGPL was added to a Nutrients 2011, 3  
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linoleic acid peroxidation system, inhibition of lipid peroxidation was significantly greater than that of 
the control α-tocopherol and as effective as the synthetic antioxidant butylated hydroxytoluene (BHT). 
Furthermore, the peptide HGPLGPL increased the expression of antioxidative enzymes in human 
hepatoma cells in vitro. 
5.2. Antioxidant Peptides from Meat Sources 
Peptides derived from porcine myofibrillar proteins using the proteases Papain and Actinase E 
represent the first report of antioxidant peptides from the myofibrillar proteins of edible meat [121]. 
Following digestion, these crude hydrolysates inhibited peroxidation of linoleic acid, DPPH 
scavenging and metal chelating activities. Purification of the peptides responsible for the antioxidant 
activity in the Papain hydrolysate resulted in the identification of five peptides: DSGVT (actin), 
IEAEGE (unknown), DAQEKLE (tropomyosin), EELDNALN (tropomyosin) and VPSIDDQEELM 
(myosin heavy chain).  
A cocktail of enzymes including pepsin, papain and proteases from the bovine pancreas and 
bacterial proteases from Streptomyces and Bacillus  polymyxa, were used to hydrolyze porcine   
collagen [122]. This resulted in the release of the antioxidant peptide QGAR, which was identified as 
residues 72–75 and 180–183 of the α1 chain of collagen. It was proposed that the QG amino acid 
residues may be a contributing factor to radical scavenging activity. 
Plasma proteins represent another valuable but under-utilized protein source. Indeed, following 
hydrolysis with Alcalase, porcine plasma hydrolysates (PPH) were found to be effective inhibitors of 
lipid oxidation, as well as effective DPPH scavengers, metal chelating and reducing agents [123]. 
Increasing the degree of hydrolysis increased antioxidant activity and the most active fractions were  
<3 kDa. The peptide with MW 441 Da and amino acid sequence HNGN was identified as the active 
antioxidant peptide. 
Chicken essence, a traditional product consumed in China was shown to possess various antioxidant 
activities including the inhibition of linoleic acid autoxidation, DPPH radical scavenging activity, 
reducing power and the ability to chelate metal ions [124]. From the extract of chicken essence, 
two peptides were identified that displayed inhibition of the autoxidation of linoleic acid in a model 
system. The first peptide with the amino acid sequence HVTEE had an induction period of   
2.49 days while the second peptide with the amino acid sequence PVPVEGV had an induction period 
of 6.50 days. 
A hydrolysate displaying strong antioxidant activity was produced following the digestion of 
venison with papain where two peptides responsible for the activity were identified, i.e., (APVPH І) 
MQIFVKTLTG and (APVPH ІІ) DLSDGEQGVL [7]. The peptide APVPH І displayed the greater 
free radical scavenging activity of the two peptides with IC50 values of 4.47, 7.82, 22.02 and 8.62 µM 
per mL for hydroxyl, DPPH, superoxide and peroxyl radicals, respectively, lower than the control  
IC50 value of vitamin C. 
6. Antimicrobial and Antiproliferative Peptides 
Antimicrobial peptides (AMPs) have been identified in a range of foods to date, with peptides 
released from milk proteins being the most plentiful source of AMPs. Indeed, AMPs have been found Nutrients 2011, 3  
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in a host of different milk proteins including the caseins [125,126] and lactoferrin [127,128]. While 
AMPs from the protein of muscle foods are less well documented, there has been one report of AMPs 
from a bovine meat source [10]. In this study, the antimicrobial and human cancer cell cytotoxic 
effects of four previously identified ACE inhibitory peptides, were evaluated. The four peptides GFHI, 
DFHING, FHG and GLSDGEWQ were assayed for antimicrobial activity against six pathogenic 
bacteria, three Gram-positive (Bacillus cereus, Listeria monocytogenes and Staphylococcus aureus) 
and three Gram-negative (Salmonella typhimurium, Escherichia coli and Pseudomonas aeruginosa). 
The peptide GLSDGEWQ inhibited the growth of S. typhimurium, B. cereus, E. coli and 
L. monocytogenes. This was the only peptide that inhibited the growth of both Gram-positive and 
Gram-negative pathogens. GFHI and FHG inhibited the growth of the pathogen P. aeruginosa. 
A cysteine rich antimicrobial peptide was produced from the digestion of oyster muscle using a 
combination of Alcalase and bromelin [26]. The peptide referred to as CgPep33 inhibited the growth 
of the pathogenic bacteria E. coli, P. aeruginosa, B. subtilis and S. aureus in addition to inhibiting the 
growth of the fungi Botrytis cinerea and Penicillium expansum. Although the sequence of the 
CgPep33 peptide was not determined, the principal amino acids present in the active fraction were C, 
L, E, D, F, Y, I and G residues. Jang et al. [10] investigated the cytotoxic effect of four AMPs from a 
bovine meat source, using the cell lines breast adenocarcinoma (MCF-7), stomach adenocarcinoma 
(AGS) and lung carcinoma (A549) cells. The peptide GFHI possessed the strongest cytotoxic effect on 
MCF-7 cells and also decreased the cell viability of AGS cells, while the peptide GLSDGEWQ 
strongly inhibited the proliferation of AGS cells. 
Peptides isolated from anchovy sauce were capable of inducing apoptosis in a human lymphoma 
cell line (U937) [129]. The peptide of interest was characterized as being hydrophobic and having a 
molecular weight of 440.9 Da [130]. Protein hydrolysates from different fish species were investigated for 
their antiproliferative activity on two human breast cancer cell lines (MCF-7/6 and MDA-MB-231) [131]. 
Hydrolysates of blue whiting, cod, plaice and salmon resulted in the significant inhibition of growth in 
both MCF-7/6 and MDA-MB-231 cell lines. 
Recently, the hydrolysate of tuna dark muscle by-product was examined for potential antiproliferative 
activity by exposure to the human breast cancer cell line MCF-7 [132]. Peptide fractions within the 
molecular weight range of 400 and 1400 Da exhibited the strongest antiproliferative activity. In these 
fractions two antiproliferative peptides were identified, i.e., LPHVLTPEAGAT from papain hydrolysate 
and PTAEGVYMVT from Protease XXIII. The IC50 value of each peptide was determined to be 
8.1 and 8.8 µM, respectively. This demonstrates once again the potential of meat products and meat 
by-products as valuable sources of bioactive peptides for incorporation into functional foods.  
7. Conclusion 
The increase in food related diseases, such as cardiovascular disease, diabetes, cancer and obesity 
has led consumers to demand food products that not only offer nutritional value but also functional and 
health benefits. Meat and fish derived peptides have been shown to exhibit antihypertensive effects 
in vivo, along with antioxidant capabilities and other bioactivities such as antimicrobial and 
antiproliferative activities in vitro. In spite of this; however, very few food products containing meat or 
fish-derived bioactive peptides are available commercially, yet these bioactives harbor huge potential. Nutrients 2011, 3  
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For example, Katsuobushi Oligopeptide LKPNM, which is found in blood pressure-lowering capsules, 
is derived from dried bonito and converted to the active form by digestive enzymes following 
ingestion [133]. The commercial chicken-meat extract known as “Brand’s Essence of Chicken” (BEC; 
Cerebos Pacific Ltd., Singapore) also claims to contain antihypertensive components [134]. These two 
examples show the potential of fish and meat bioactive peptides for use as functional ingredients in 
foods. However, the ability of bioactive peptides to exert a physiological effect in vivo is dependent on 
the bioavailability of the peptide. This factor is dependent on the resistance of the peptide to hydrolysis 
by peptidases of both the intestinal tract and serum, and its ability to be absorbed across the intestinal 
epithelium [61]. Therefore, when identifying bioactive peptides for the development of meat and   
fish-based nutraceutical products, this fact should be taken into account. 
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